3-(4-Hydroxymethylbenzoyl)-1-pentylindole

3-(4-Hydroxymethylbenzoyl)-1-pentylindole
Names
	Preferred IUPAC name [4-(Hydroxymethyl)phenyl](1-pentyl-1H-indol-3-yl)methanone
Identifiers
CAS Number	1391485-19-0;
3D model (JSmol)	Interactive image;
ChemSpider	52084877;
PubChem CID	117587639;
UNII	W64GU7350V;
CompTox Dashboard (EPA)	DTXSID701183123 ;
	InChI InChI=1S/C21H23NO2/c1-2-3-6-13-22-14-19(18-7-4-5-8-20(18)22)21(24)17-11-9-16(15-23)10-12-17/h4-5,7-12,14,23H,2-3,6,13,15H2,1H3 Key: KAXVGIUZJKXDPE-UHFFFAOYSA-N;
	SMILES CCCCCN1C=C(C2=CC=CC=C21)C(=O)C3=CC=C(C=C3)CO;
Properties
Chemical formula	C21H23NO2
Molar mass	321.420 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

3-(4-Hydroxymethylbenzoyl)-1-pentylindole is a synthetic cannabinoid. It is planned to be scheduled (in group I-N) in Poland.^[1] It has been reported to the EMCDDA and Europol for the first time in 2010^[2] under the terms of European Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances.^[3]

References

^ http://www.mz.gov.pl/wwwmz/index?mr=q491&ms=382&ml=pl&mi=382&mx=0&mt=&my=131&ma=030747 http://www.mz.gov.pl/wwwfiles/ma_struktura/docs/ustawa_narkoman_201209171553.pdf Archived 2015-12-22 at the Wayback Machine "[E]kspertyza [opracowana] przez Katedrę i Zakład Farmakologii Doświadczalnej i Klinicznej Warszawskiego Uniwersytetu Medycznego [...] potwierdziła zasadność objęcia kontrolą ustawową [...] syntetycznych kanabinoidów: JWH-015, JWH-098, JWH-251, JWH-307, AM-2201, 3-(4-hydroksymetylobenzoilo)-1-pentyloindol" ("Department of Experimental and Clinical Pharmacology of Medical University of Warsaw evaluated that synthetic cannabinoids JWH-015, JWH-098, JWH-251, JWH-307, AM-2201, 3-(4-hydroxymethylbenzoyl)-1-pentylindole need to be scheduled.", accessed 30 April 2013)
^ "Annex 2 – New psychoactive substances reported to the EMCDDA and Europol for the first time in 2010 under the terms of Council Decision 2005/387/JHA" (PDF). European Monitoring Centre for Drugs and Drug Addiction.
^ "32005D0387 - EN - EUR-Lex: European Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances". EUR-Lex (in Afrikaans). 2005-05-10. Retrieved 2021-11-24.

[1] ttp://www.mz.gov.pl/wwwmz/index?mr=q491&ms=382&ml=pl&mi=382&mx=0&mt=&my=131&ma=030747 http://www.mz.gov.pl/wwwfiles/ma_struktura/docs/ustawa_narkoman_201209171553.pdf Archived 2015-12-22 at the Wayback Machine "[E]kspertyza [opracowana] przez Katedrę i Zakład Farmakologii Doświadczalnej i Klinicznej Warszawskiego Uniwersytetu Medycznego [...] potwierdziła zasadność objęcia kontrolą ustawową [...] syntetycznych kanabinoidów: JWH-015, JWH-098, JWH-251, JWH-307, AM-2201, 3-(4-hydroksymetylobenzoilo)-1-pentyloindol" ("Department of Experimental and Clinical Pharmacology of Medical University of Warsaw evaluated that synthetic cannabinoids JWH-015, JWH-098, JWH-251, JWH-307, AM-2201, 3-(4-hydroxymethylbenzoyl)-1-pentylindole need to be scheduled.", accessed 30 April 2013)

[2] "Annex 2 – New psychoactive substances reported to the EMCDDA and Europol for the first time in 2010 under the terms of Council Decision 2005/387/JHA" (PDF). European Monitoring Centre for Drugs and Drug Addiction.

[3] "32005D0387 - EN - EUR-Lex: European Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances". EUR-Lex (in Afrikaans). 2005-05-10. Retrieved 2021-11-24.

[1]

[2]

[3]

See also

References